Inactive Instrument
InMed Pharmaceuticals Inc Stock Canadian Securities Exchange
Stocks
IN
CA4576371062
Biotechnology & Medical Research
| Market Cap | 6.92M 4.87M 4.28M 3.94M 3.67M 463M 7.06M 47.36M 18.35M 227M 18.29M 17.9M 791M | P/E 2024 |
-0.26x | P/E 2025 | -0.39x |
|---|---|---|---|---|---|
| Enterprise Value | -3.46M -2.43M -2.14M -1.97M -1.83M -231M -3.53M -23.67M -9.17M -114M -9.14M -8.94M -395M | EV / Sales 2024 |
-714,273x | EV / Sales 2025 | -1,305,911x |
| Free-Float |
99.88% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: InMed Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 63 | 16/06/2016 |
Netta Jagpal
DFI | Director of Finance/CFO | 53 | 20/02/2024 |
| Chief Operating Officer | 57 | 15/07/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Eric Adams
BRD | Director/Board Member | 63 | 16/06/2016 |
Andrew Hull
CHM | Chairman | 63 | - |
Nicole Lemerond
BRD | Director/Board Member | 51 | 08/08/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 6.92M | |
| -2.19% | +6.01% | +66.90% | +127.13% | 57.65B | |
| +0.55% | +17.77% | +80.01% | +100.93% | 55.14B | |
| -0.10% | +3.18% | -13.42% | -13.67% | 23.53B | |
| +0.09% | +3.19% | +9.36% | +414.51% | 23.11B | |
| -1.93% | +11.11% | +34.89% | -7.86% | 18.14B | |
| +0.28% | +5.51% | +36.93% | -30.58% | 16.84B | |
| -1.12% | +1.25% | +22.72% | +179.82% | 13.68B | |
| +0.14% | +9.60% | +33.31% | - | 12.97B | |
| -2.93% | +2.36% | +73.83% | +131.10% | 12.38B | |
| Average | -0.73% | +5.56% | +38.28% | +112.67% | 25.94B | |
| Weighted average by Cap. | -0.77% | +4.62% | +47.47% | +116.01% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.6 3.24 2.84 2.62 2.44 307.78 4.69 31.47 12.19 151.07 12.16 11.89 525.78 | 4.94 3.48 3.06 2.81 2.62 330.87 5.04 33.83 13.11 162.41 13.07 12.78 565.22 |
| Net income | -7.68M -5.4M -4.75M -4.37M -4.07M -514M -7.83M -52.53M -20.35M -252M -20.29M -19.85M -878M | -8.16M -5.75M -5.05M -4.64M -4.33M -546M -8.33M -55.86M -21.64M -268M -21.58M -21.11M -933M |
| Net Debt | -5.65M -3.98M -3.49M -3.22M -3M -378M -5.77M -38.68M -14.99M -186M -14.94M -14.62M -646M | -10.38M -7.31M -6.42M -5.91M -5.5M -695M -10.59M -71.03M -27.52M -341M -27.44M -26.84M -1.19B |
Employees
-
